File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Recipient FK506 pretreatment regimens in rat small bowel transplantation: allograft survival, function, and systemic infection

TitleRecipient FK506 pretreatment regimens in rat small bowel transplantation: allograft survival, function, and systemic infection
Authors
Issue Date2000
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/jpedsurg
Citation
Journal of Pediatric Surgery, 2000, v. 35, p. 1600-1605 How to Cite?
Abstract
Purpose: Successful Small Bowel Transplantation Requires Effective Immunosuppression That Preserves Intestinal Function But Avoids Opportunistic Infection. This Study Aims To Evaluate Fk506 As A Single Immunosuppressant In Different Pretreatment Regimens In A Rat High Responder Strain Combination. Methods: Lewis → Da Rat Heterotopic Small Bowel Transplantation Was Performed. Studied Groups Were (1) Untreated Control, N = 12; (2) Fk-1, N = 8; (3) Fk-3, N = 8. Fk506 (2 Mg/Kg/D, Intramuscularly) Was Given To The Recipients For 1 Day (Fk-1) And 3 Days (Fk-3) Before Small Bowel Transplantation, Followed By 2 Weeks Of Subtherapeutic Treatment (0.3 Mg/Kg/D, Intramuscularly) After Small Bowel Transplantation. Syngeneic Small Bowel Transplantation Also Was Performed (N = 8). Fk Blood Levels, Maltose Absorption Test, Histology, And Bacteriology Were Performed At Different Postoperative Days. Results: Allograft Survival Was Prolonged Significantly With Fk Pretreatment, Being More So In Fk-3 Group (Fk-1, 22.2 ± 1.5 D; Fk-3, 40.7 ± 14.1 D; Control, 6.6 ± 0.8 D; P < .01). In The First Postoperative Week, Fk Blood Level Was Significantly Higher In Fk-3 Group (19.8 ± 1.5 Ng/Ml) Than In Fk-1 Group (5.0 ± 0.4 Ng/Ml; P < .05). There Was No Evidence Of Systemic Infection In Either Fk-Treated Group. For Maltose Absorption, Control Allograft Was Abnormal On Day 7 Correlating To Severely Damaged Intestinal Architecture. In Contrast, Fk-Treated Allografts Showed Well-Protected Intestinal Structure And Normal Absorption On Days 7 And 21. Conclusion: High Fk506 Blood Levels In The First Postoperative Week, Achieved With Fk Pretreatment, Prolonged Intestinal Allograft Survival And Preserved Intestinal Structure And Function Without Allowing Systemic Infection. Copyright (C) 2000 By W.B. Saunders Company.
Persistent Identifierhttp://hdl.handle.net/10722/83352
ISSN
2013 Impact Factor: 1.311
2013 SCImago Journal Rankings: 0.811
ISI Accession Number ID
References

 

Author Affiliations
  1. Bristol Royal Hospital for Children
  2. The University of Hong Kong
  3. Imperial College London
DC FieldValueLanguage
dc.contributor.authorGuo, WHen_HK
dc.contributor.authorTian, Len_HK
dc.contributor.authorYuen, ZWen_HK
dc.contributor.authorChan, KLen_HK
dc.contributor.authorWo, JYHen_HK
dc.contributor.authorNicholls, Gen_HK
dc.contributor.authorDallman, Men_HK
dc.contributor.authorTam, PKHen_HK
dc.date.accessioned2010-09-06T08:40:00Z-
dc.date.available2010-09-06T08:40:00Z-
dc.date.issued2000en_HK
dc.identifier.citationJournal of Pediatric Surgery, 2000, v. 35, p. 1600-1605en_HK
dc.identifier.issn0022-3468en_HK
dc.identifier.urihttp://hdl.handle.net/10722/83352-
dc.description.abstractPurpose: Successful Small Bowel Transplantation Requires Effective Immunosuppression That Preserves Intestinal Function But Avoids Opportunistic Infection. This Study Aims To Evaluate Fk506 As A Single Immunosuppressant In Different Pretreatment Regimens In A Rat High Responder Strain Combination. Methods: Lewis → Da Rat Heterotopic Small Bowel Transplantation Was Performed. Studied Groups Were (1) Untreated Control, N = 12; (2) Fk-1, N = 8; (3) Fk-3, N = 8. Fk506 (2 Mg/Kg/D, Intramuscularly) Was Given To The Recipients For 1 Day (Fk-1) And 3 Days (Fk-3) Before Small Bowel Transplantation, Followed By 2 Weeks Of Subtherapeutic Treatment (0.3 Mg/Kg/D, Intramuscularly) After Small Bowel Transplantation. Syngeneic Small Bowel Transplantation Also Was Performed (N = 8). Fk Blood Levels, Maltose Absorption Test, Histology, And Bacteriology Were Performed At Different Postoperative Days. Results: Allograft Survival Was Prolonged Significantly With Fk Pretreatment, Being More So In Fk-3 Group (Fk-1, 22.2 ± 1.5 D; Fk-3, 40.7 ± 14.1 D; Control, 6.6 ± 0.8 D; P < .01). In The First Postoperative Week, Fk Blood Level Was Significantly Higher In Fk-3 Group (19.8 ± 1.5 Ng/Ml) Than In Fk-1 Group (5.0 ± 0.4 Ng/Ml; P < .05). There Was No Evidence Of Systemic Infection In Either Fk-Treated Group. For Maltose Absorption, Control Allograft Was Abnormal On Day 7 Correlating To Severely Damaged Intestinal Architecture. In Contrast, Fk-Treated Allografts Showed Well-Protected Intestinal Structure And Normal Absorption On Days 7 And 21. Conclusion: High Fk506 Blood Levels In The First Postoperative Week, Achieved With Fk Pretreatment, Prolonged Intestinal Allograft Survival And Preserved Intestinal Structure And Function Without Allowing Systemic Infection. Copyright (C) 2000 By W.B. Saunders Company.en_US
dc.languageengen_HK
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/jpedsurgen_HK
dc.relation.ispartofJournal of Pediatric Surgeryen_HK
dc.titleRecipient FK506 pretreatment regimens in rat small bowel transplantation: allograft survival, function, and systemic infectionen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0022-3468&volume=35&spage=1600&epage=1605&date=2000&atitle=Recipient+FK506+pretreatment+regimens+in+rat+small+bowel+transplantation:+allograft+survival,+function,+and+systemic+infectionen_HK
dc.identifier.emailChan, KL: klchan@HKUCC.hku.hken_HK
dc.identifier.emailTam, PKH: paultam@hkucc.hku.hken_HK
dc.identifier.authorityTam, PKH=rp00060en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1053/jpsu.2000.18326en_US
dc.identifier.pmid11083432-
dc.identifier.scopuseid_2-s2.0-0033759052en_US
dc.identifier.hkuros62044en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0033759052&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume35en_US
dc.identifier.issue11en_US
dc.identifier.spage1600en_US
dc.identifier.epage1605en_US
dc.identifier.isiWOS:000165100100017-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats